Searchable abstracts of presentations at key conferences in endocrinology

ea0063gp237 | Anterior and Posterior Pituitary | ECE2019

Diagnostic accuracy of copeptin in the diagnosis of diabetes insipidus after pituitary surgery

Ferrante Emanuele , Serban Andreea , Sala Elisa , Cremaschi Arianna , Grassi Giorgia , Locatelli Marco , Arosio Maura , Mantovani Giovanna

Background: Routine clinical use of arginine-vasopressin (AVP) is limited by its small molecular size and pre-analytical errors. In contrast, copeptin – a peptide of 39 amino acids co-secreted with arginine-vasopressin (AVP) - is a stable protein and its measurement represents a reliable measure of AVP concentration. The aim of this study was to analyze diagnostic role of copeptin in diagnosis of diabetes insipidus (DI) in patients treated for hypothalamic-pituitary disea...

ea0041ep853 | Pituitary - Basic | ECE2016

Human non-functioning pituitary tumors invasiveness: inhibitory effects of dopamine receptor type 2 (DRD2) agonist and cofilin involvement

Peverelli Erika , Giardino Elena , Treppiedi Donatella , Locatelli Marco , Vaira Valentina , Ferrero Stefano , Spada Anna , Mantovani Giovanna

Non-functioning pituitary tumors (NFPTs), although benign in nature, frequently present local invasiveness that strongly reduces neurosurgery success. Medical therapy is still under debate, although dopamine (DA) receptor 2 (DRD2) agonists may induce tumor shrinkage in some patients. Aims of this study were: 1) to evaluate the effect of DR2D agonist BIM53097 on migration and invasion of NFPT cells, 2) to investigate the molecular mechanisms regulating the motility of these cel...

ea0056p823 | Pituitary - Clinical | ECE2018

Recovery of the adrenal function after pituitary surgery in patients with Cushing Disease: remission or recurrence?

Serban Andreea , Verrua Elisa , Sala Elisa , Locatelli Marco , Arosio Maura , Mantovani Giovanna , Ferrante Emanuele

Background: The treatment of choice in patients with Cushing Disease (CD) is pituitary surgery (PS). A successful PS is generally followed by adrenal insufficiency (AI). Although the remission rate after PS may reach 96.6% of cases, approximately 1/3 of cured patients experience the recurrence of the disease during lifetime. The aim of this study was to analyze the duration of AI in relation with the recurrence of CD.Materials and methods: We performed a...

ea0063p261 | Pituitary and Neuroendocrinology 1 | ECE2019

Novel insight into ACTH-secreting pituitary tumors biological behavior: somatostatin receptor type 5 (SST5) modulation by ubiquitin specific peptidase 8 (USP8)

Peverelli Erika , Treppiedi Donatella , Giardino Elena , Catalano Rosa , Mangili Federica , Vercesi Pietro , Locatelli Marco , Spada Anna , Arosio Maura , Mantovani Giovanna

Cushing’s Disease (CD) is a rare condition characterized by an overproduction of ACTH by an ACTH-secreting pituitary tumor, resulting in excess of cortisol release by the adrenal glands. Pasireotide is the pituitary-targeted drug approved to treat adult patients. Its mechanism of action seems to rely on the preferential binding to the highly expressed somatostatin receptor in corticotroph tumors, SST5. Recently, somatic mutations in the deubiquitinase USP8 gene h...

ea0063p265 | Pituitary and Neuroendocrinology 1 | ECE2019

Somatostatin receptor type 2 trafficking through the cytoskeleton: role of scaffolding proteins Filamin A and β-arrestin 2

Treppiedi Donatella , Giardino Elena , Catalano Rosa , Mangili Federica , Locatelli Marco , Spada Anna , Arosio Maura , Mantovani Giovanna , Peverelli Erika

The high expression of somatostatin receptor 2 (SST2) in growth hormone (GH)-secreting tumors represents the rationale for the clinical use of somatostatin analogs (SSAs) in acromegaly. However, about one third of patients displays resistance to SSAs and, to date, the responsible molecular mechanisms are still under investigation. Recently, the cytoskeletal protein Filamin A (FLNA) and the scaffolding proteins β-arrestins have emerged as key modulators of the responsivene...

ea0063p267 | Pituitary and Neuroendocrinology 1 | ECE2019

Somatostatin receptor type 5 modulation by Filamin A in ACTH-secreting pituitary tumors

Treppiedi Donatella , Giardino Elena , Catalano Rosa , Mangili Federica , Locatelli Marco , Spada Anna , Arosio Maura , Mantovani Giovanna , Peverelli Erika

Cushing’s disease (CD) is a rare disorder of chronic hypercortisolism due to an adrenocorticotropic hormone (ACTH)-secreting pituitary tumor. Pasireotide, a multireceptor-targeted somatostatin (SST) analog with high binding affinity for the predominant SST receptor in human corticotroph tumors, SST5, has been recently approved to treat adult patients for whom surgery failed or does not represent a suitable option. However, to date, the molecular predictors of antisecretor...

ea0049ep924 | Pituitary - Basic | ECE2017

SSTR2 inhibits GH-secreting pituitary tumoral cells migration and invasion by increasing cofilin phosphorylation

Peverelli Erika , Giardino Elena , Treppiedi Donatella , Locatelli Marco , Lania Andrea G , Arosio Maura , Spada Anna , Mantovani Giovanna

Although generally benign, pituitary tumors frequently present local invasiveness that strongly reduces neurosurgery success. We recently demonstrated a role for the actin binding protein cofilin in promoting non functioning pituitary tumors invasiveness and an inhibitory effect of dopamine receptor type 2. Somatostatin (SS) receptor type 2 (SSTR2) is the main target of pharmacological therapy of GH-secreting pituitary tumors, reducing both GH secretion and cell proliferation,...

ea0037ep806 | Pituitary: clinical | ECE2015

Psychological and neurocognitive evaluation in patients with pituitary adenoma

Sala Elisa , Zarino Barbara , Malchiodi Elena , Verrua Elisa , Carosi Giulia , Locatelli Marco , Rampini Paolo , Carrabba Giorgio , Spada Anna , Mantovani Giovanna

Reduced health-related quality of life (HRQoL) and impairment in neurocognitive functions are a possible complaint in patients with pituitary adenoma. Psychiatric comorbidities in Cushing’s disease are well known. However recent studies showed HRQoL reduction and psychiatric symptoms in patients with pituitary disease with or without hormonal excess. Aim of this study is to analyse HRQoL, psychiatric symptoms and neurocognitive functions in patients with pituitary adenoma...

ea0016p300 | Endocrine tumours | ECE2008

Proteomic profile of GH-secreting versus non-functioning pituitary tumors

Verpelli Chiara , Mantovani Giovanna , Locatelli Marco , Bello Lorenzo , Peccoz Paolo Beck , Spada Anna , Sala Claudio , Lania Andrea

GH-secreting and non-functioning pituitary tumors are clinically distinct, usually benign but potentially locally aggressive lesions originating from the replication of a single mutated pituitary cell. As for the underlying genetic and epigenetic alterations, also the patterns of activation of specific signaling pathways as well as the prognostic molecular factors leading to local invasiveness are, to date, largely unknown. In this study, we used two-dimensional electrophoresi...

ea0063gp165 | Obesity (1) | ECE2019

Role of invasive and non-invasive diagnostic tests in differential diagnosis of ACTH-dependent Cushing’s syndrome

Barbot Mattia , Ferrante Emanuele , Ceccato Filippo , Daniele Andrea , Lizzul Laura , Cuman Margherita , Monteleone Valerio , Serban Andreea , Sala Elisa , Locatelli Marco , Arosio Maura , Boscaro Marco , Scaroni Carla , Mantovani Giovanna

Background: Differential diagnosis of ACTH-dependent hypercortisolism is crucial to indicate a proper treatment and is based on CRH-, high-dose dexamethasone suppression-test (HDDST) and pituitary MRI. However, up to 50% of cases of Cushing’s disease (CD) present a negative MRI or a visible lesion < 6 mm. In these patients, guidelines suggest to perform bilateral inferior petrosal sinus sampling (BIPSS) in order to establish a correct diagnosis. Aim of this study was ...